Pharmaceutical
Medical Devices
Technology
Daiichi Sankyo
$40.549876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$40.54
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.03 (-0.07%) Today
-$0.03 (-0.07%) Today
Why Robinhood?
You can buy or sell Daiichi Sankyo and other stocks, options, ETFs, and crypto commission-free!
About
Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products. It operates through the following segments: Daiichi Sankyo Group and Ranbaxy Group. Read More The Daiichi Sankyo Group segment comprises of Daiichi Sankyo Co., Ltd. and its subsidiaries. The Ranbaxy Group segment includes its core company, Ranbaxy Laboratories Ltd. Both group segments deal with business activities in prescription drugs and general pharmaceutical products. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan. DSNKY is listed on the Pink Current market tier. OTC market data is provided by OTC Markets Group, Inc (otcmarkets.com).
Employees
14,446
Headquarters
Tokyo, Tokyo
Founded
2005
Market Cap
26.28B
Price-Earnings Ratio
44.14
Dividend Yield
1.60
Average Volume
15.57K
High Today
$40.57
Low Today
$40.28
Open Price
$40.57
Volume
2.20K
52 Week High
$43.74
52 Week Low
$30.00
Collections
Pharmaceutical
Medical Devices
Technology
Health
Medical
Asia (Non-China)
Asia
News
PR Newswire6h
Data from the Non-interventional EMIT-AF/VTE Study Shows Low Thromboembolic and Bleeding Event Rates in Unselected Elderly AF/VTE Patients on Oral, Once-daily LIXIANA®▼ Undergoing Diagnostic or Therap
MUNICH, March 19, 2019 /PRNewswire/ -- In 2019, the Edoxaban Clinical Research Programme will deliver new evidence on LIXIANA ® ▼ (edoxaban) use in clinical practice. EMIT-AF/VTE is one of the first sets of data to be presented EMIT-AF/VTE is a large observational, multicentre, multinational study on edoxaban peri-procedural management and outcomes It is the first large prospective, non-interventional study to apply the European Heart Rhythm Association (EHRA) bleeding risk classification in edoxaban rou...
PR Newswire7h
CLEAR Wisdom Demonstrated First-in-class, Oral, Once-daily, ACL Inhibitor Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP
MUNICH and ANN ARBOR, Michigan, March 19, 2019 /PRNewswire/ -- Daiichi Sankyo Europe GMbH (hereafter, 'Daiichi Sankyo') and Esperion (NASDAQ: ESPR) today announced that the Phase 3 results from CLEAR Wisdom of first-in-class, oral, once-daily ATP citrate lyase (ACL) inhibitor, bempedoic acid, were presented at the ACC Scientific Sessions & Expo in New Orleans.
PR NewswireMar 18
Daiichi Sankyo Presents Positive Results of the First Randomised, Controlled Trial of Uninterrupted Oral, Once-daily LIXIANA®▼ (edoxaban) in Atrial Fibrillation Patients Undergoing Catheter Ablation
MUNICH, March 18, 2019 /PRNewswire/ -- ELIMINATE-AF is the first set of data presented in 2019 from the Edoxaban Clinical Research Programme, which will deliver new evidence to support the use of edoxaban in clinical practice Late-breaking data presented at EHRA 2019, the annual congress of the European Heart Rhythm Association, shows ELIMINATE-AF met primary efficacy and safety objectives, demonstrating low thromboembolic and bleeding event rates 1 ELIMINATE-AF provides evidence that uninterrupted LIXIA...
Price Paid on Robinhood
10% Higher
Right Now
52 Week Low
$30.00
Average Price Paid
$36.85
52 Week High
$43.74